Researchers harness Cas13 as an antiviral agent and diagnostic tool for RNA-based viruses
https://news.harvard.edu/gazette/story/2019/10/researchers-can-prog...
The need for new antiviral approaches is urgent. In the past 50 years, 90 clinically approved antiviral drugs have been produced, but they treat only nine diseases — and viral pathogens can rapidly evolve resistance to treatment. Only 16 viruses have FDA-approved vaccines.
To explore new antiviral strategies, the team focused on Cas13, which naturally targets viral RNA in bacteria. The enzyme can be programmed to target specific sequences of RNA with few limitations, is relatively easy to get into cells, and has been well-studied in mammalian cells by researchers including Broad Institute core member Feng Zhang.
The team first screened a suite of RNA-based viruses in search of viral RNA sequences that Cas13 could efficiently target. They primarily looked for pieces that are both least likely to mutate and most likely, when cut, to disable a virus.
“In theory, you could program Cas13 to attack virtually any part of a virus,” explained Myhrvold. “But there’s huge diversity within and among species, and much of the genome changes rapidly as a virus evolves. If you’re not careful, you could be going after a target that will ultimately have no effect.”
The researchers computationally identified thousands of sites, in hundreds of viral species, which could be effective targets for Cas13.
Three-in-one system
With a list of potential viral RNA targets in hand, the team could then program Cas13 to seek out and cut any of these nucleic acid sequences by engineering the enzyme’s guide RNA.
The researchers experimentally tested Cas13’s activity in human cells infected with one of three distinct RNA-based viruses: lymphocytic choriomeningitis virus (LCMV), influenza A virus (IAV), and vesicular stomatitis virus (VSV). They introduced the Cas13 gene and an engineered guide RNA into the cells, and 24 hours later, exposed the cells to the virus. After another 24 hours, the Cas13 enzymes had reduced the level of viral RNA in the cell cultures by up to 40-fold.
The team further explored Cas13’s effect on virus infectivity — in other words, how much of the remaining virus could actually continue to infect human cells. The data indicated that eight hours after viral exposure, Cas13 had reduced the infectivity of the flu virus by more than 300-fold.
To add a diagnostic component, the researchers also incorporated the Cas13-based nucleic acid detection technology SHERLOCK. The resulting CARVER system could rapidly measure the remaining levels of viral RNA in a sample.
Tags:
Need help? Visit our Support Group for help from our friendly Admins and members!
Visit The Temple
on Facebook:
Posted by Atrayo on April 17, 2024 at 10:26am 0 Comments 1 Like
Posted by Atrayo on April 14, 2024 at 7:54am 0 Comments 1 Like
Posted by Atrayo on April 6, 2024 at 1:51pm 0 Comments 1 Like
Posted by Ghillie Dhu on March 2, 2024 at 5:06am 4 Comments 0 Likes
Posted by Atrayo on February 22, 2024 at 12:54am 0 Comments 1 Like
Posted by Atrayo on February 14, 2024 at 6:57pm 0 Comments 1 Like
Posted by Bill Walker on February 1, 2024 at 8:15pm 1 Comment 1 Like
Posted by Sky a.k.a. JD Aeon on January 7, 2024 at 4:43am 1 Comment 5 Likes
Posted by Atrayo on December 29, 2023 at 1:04pm 0 Comments 1 Like
Posted by Kitt on December 14, 2023 at 8:55pm 2 Comments 4 Likes
Posted by Atrayo on November 29, 2023 at 11:21pm 0 Comments 2 Likes
Posted by 06iiris on October 13, 2023 at 8:30am 0 Comments 1 Like
Posted by 06iiris on October 13, 2023 at 7:00am 0 Comments 0 Likes
Posted by 06iiris on October 12, 2023 at 3:30pm 0 Comments 0 Likes
Posted by 06iiris on October 12, 2023 at 6:00am 0 Comments 0 Likes
Posted by 06iiris on October 12, 2023 at 5:30am 0 Comments 0 Likes
Posted by 06iiris on October 11, 2023 at 1:00pm 0 Comments 0 Likes
Posted by 06iiris on October 11, 2023 at 8:30am 0 Comments 0 Likes
Posted by 06iiris on October 9, 2023 at 7:30am 0 Comments 0 Likes
Posted by 06iiris on October 5, 2023 at 1:00pm 0 Comments 0 Likes
Added by Imelda James 0 Comments 0 Likes
Added by Imelda James 0 Comments 0 Likes
Added by Bryan_Thoth 0 Comments 0 Likes
© 2024 Created by Bryan Powered by